PLEASE SEND YOUR ABSTRACTS TO:
Nordic Melanoma Meeting 2021 Abstract and Case Report Instructions
High quality Abstracts and Case Reports will be selected by the Nordic Melanoma Meeting Scientific Program Committee for presentation at the 2021 Nordic Melanoma Meeting. All types of melanoma-related research are eligible for submission. The best Case Report will also be considered for publication in Acta Oncologica as a short report.
Abstract submissions are considered for all types of presentation, and as such authors are permitted to state a preference for type of presentation at the time of submission. Abstracts will be judged solely on the data submitted.
Send your abstract (max. 1 A4 page, font: 12) including title, authors and their institutes, purpose of study, methods, results, conclusions and acknowledgement of research support. The abstract can include one picture. The case report should consist an introduction, case presentation and discussion, if possible (max. 1 A4 page, font: 12). Abstracts and Case Reports should be sent by June 30th 2021.
Each first author (presenting author) will receive an email acknowledging receipt of the abstract after completing the submission. The first author (presenting author) receives a decision letter from the Program Committee not later than August 16th 2021. The Scientific Program Committee will determine the presentation format for accepted abstracts.
THE TYPES OF PRESENTATIONS INCLUDE THE FOLLOWING:
Oral Abstract Sessions
This type of session includes 15-minute presentations of abstracts representing important clinical and translational research findings by topic category. Presenting authors should use PowerPoint presentation (max 8 slides) to accompany their oral presentation. The presenter should reserve 5 minutes of the allocated time for discussion of the presentation.
Selected abstracts will be displayed on poster boards and grouped by topic, and for show during the whole meeting. First authors should be available at their poster for during coffee breaks to answer questions informally from Meeting attendees.
We encourage the participants to submit a case report (max. 1 A4 page, font: 12) concerning toxicity of immunotherapy to be discussed during the meeting. The case report should be submitted by June 30th 2021, so the Scientific Program Committee can select those that will be presented at the case report session. The presenting author will receive a decision letter from the Program Committee not later than August 16th 2021. It is important to choose a title reflecting the type of toxicity that will be discussed as ideally, selected case reports should cover different type of adverse effects. Attendees can submit multiple clinical cases. Please note that the focus of this case report session is on "toxicity of immunotherapy". There will be no template for this Case Report, however, please prepare a 5 min presentation (max. 5 PowerPoint slides) per case + max a 1 A4 page abstract.